{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-073403","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.235988+00:00","generated_at":"2026-05-23T20:47:25.255954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025","bullets":["FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.","Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.","FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.","First FB102 vitiligo patient dosing expected shortly."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-073403","json":"https://secwatch.observer/filing/0001193125-25-073403.json","markdown":"https://secwatch.observer/filing/0001193125-25-073403.md","text":"https://secwatch.observer/filing/0001193125-25-073403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/0001193125-25-073403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312525073403/d876988d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T20:47:25.255954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}